title: Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer.
abstract: From January 1990 to April 1993, 60 oesophageal cancer patients were enrolled in a protocol of non-surgical treatment that consisted of induction chemotherapy followed by concurrent chemoradiotherapy. Induction chemotherapy consisted of cisplatin 40 mg/m2 intravenous bolus days 1, 2, 14, 15; 24 h continuous infusion of 5-fluorouracil (5-FU) 1000 mg/m2 days 1 and 14; leucovorin 20 mg/m2 days 1 and 14 given before and with 5-FU; bleomycin 30 UI days 1 and 14; mitomycin C 10 mg/m2 day 14. Concurrent chemoradiotherapy consisted of 60 Gy (6 weeks) from day 21 and cisplatin 70 mg/m2 days 28, 42 and 56; leucovorin 20 mg/m2 followed by 5-FU 425 mg/m2 days 28, 35, 42, 49 and 56. Complete response occurred in 44 of 55 evaluable patients (80%). The median survival is 32 months; the actuarial survival at 40 months is 35% (CI 18-53). These results appear improved over those reported with surgery or radiation alone, and suggest that organ preservation as a secondary treatment goal should be vigorously investigated.
authors.affiliation: Hospital Municipal de Gastroenterologia, Caseros, Argentina.
authors.forename: E
authors.initials: E
authors.lastname: Roca
authors.forename: E
authors.initials: E
authors.lastname: Pennella
authors.forename: M
authors.initials: M
authors.lastname: Sardi
authors.forename: S
authors.initials: S
authors.lastname: Carraro
authors.forename: M
authors.initials: M
authors.lastname: Barugel
authors.forename: C
authors.initials: C
authors.lastname: Milano
authors.forename: A
authors.initials: A
authors.lastname: Fiorini
authors.forename: R
authors.initials: R
authors.lastname: Giglio
authors.forename: G
authors.initials: G
authors.lastname: Gonzalez
authors.forename: R
authors.initials: R
authors.lastname: Kneitschel
authors.forename: E
authors.initials: E
authors.lastname: Aman
authors.forename: A
authors.initials: A
authors.lastname: Jarentchuk
authors.forename: C
authors.initials: C
authors.lastname: Blajman
authors.forename: J
authors.initials: J
authors.lastname: Nadal
authors.forename: M T
authors.initials: MT
authors.lastname: Santarelli
authors.forename: A
authors.initials: A
authors.lastname: Navigante
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction; D016019:Survival Analysis
chemical_list: D008937:Mitomycins; D001761:Bleomycin; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil